Supriya Lifescience: Independent Directors Dinesh Modi and Dileep Jain Complete Tenure
Supriya Lifescience Limited announced that Independent Directors Mr. Dinesh Navnitlal Modi and Mr. Dileep Kumar Jain completed their five-year tenures on March 24, 2026. The board conveyed appreciation for their contributions. Committees were reconstituted on February 09, 2026.
The departure of independent directors upon completion of their tenure is a standard governance procedure. Unless there are specific concerns raised or the directors were instrumental in a particular strategic initiative, the immediate impact is typically low.
The announcement concerns the completion of tenure for independent directors, which is a routine procedural event and does not inherently carry positive or negative financial implications for the company. The board's appreciation is standard practice.
Supriya Lifescience Limited has announced the completion of the tenure for two of its Independent Directors, Mr. Dinesh Navnitlal Modi (DIN: 00004556) and Mr. Dileep Kumar Jain (DIN: 00380311). Their five-year terms concluded on March 24, 2026.
The Board of Directors expressed their sincere appreciation for the contributions made by both directors during their association with the company. The announcement also detailed the reconstituted committees following a Board Meeting held on February 09, 2026. The Audit Committee now includes Mr. Hari K. as Chairman, Dr. Ganapati Dadasaheb Yadav, Dr. Satish Waman Wagh, and Mr. Manish Panchal. The Nomination and Remuneration Committee is chaired by Mr. Hari K. and includes Dr. Sunil Subhash Bhagwat and Mr. Manish Panchal. The Stakeholders’ Relationship Committee is chaired by Mr. Manish Panchal, with Dr. Saloni Satish Wagh and Dr. Satish Waman Wagh as members.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under board changes. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.